 VolitionRx NYSE-A:VNRX Limited ended the second quarter with 16.7 million in the bank to help advance research and commercialization efforts for its Nucleosomics platform for blood tests. The Henderson, Nevada-based epigenetics company had a busy quarter that saw it receive a CE Mark for its Nu.Q Netosis NETs test in Europe and reveal new clinical studies for NETs in the US. 